logo
Plus   Neg
Share
Email

Pfizer Unit Reaches Patent Litigation With Intelliject, Sanofi-Aventis

Mylan Inc. (MYL) and Pfizer Inc. (PFE) Thursday announced that Meridian Medical Technologies, a Pfizer subsidiary, has agreed with Intelliject and Sanofi-Aventis to resolve pending patent litigation related to Intelliject's new drug application for its epinephrine auto-injector known as e-cue.

E-cue will be manufactured and marketed by Sanofi-Aventis. Meridian manufactures EpiPen Auto-Injector and Mylan Specialty markets and distributes the product in the United States.

As per the settlement, Intelliject and Sanofi-Aventis may launch e-cue no earlier than November 15, 2012, subject to receipt of final approval from the U.S. Food and Drug Administration.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Harley-Davidson Inc. (HOG) disclosed in a regulatory filing that it will be implementing a plan to shift production of motorcycles for the European Union destinations from the U.S. to its international facilities to avoid European Union's tariff. The company expects ramping-up production in international... Want to know when you will die? Google can tell. Google has tested an artificial intelligence or AI computer system that can predict whether hospital patients will pass away 24 hours after admission. Not just that, the system can also guess the length of a patient's stay in hospital and his chances of being readmitted. Piper Jaffray analyst Michael Olson said Monday that the video-game industry revenue could be 100 percent digital by 2022 and result in publisher margins being "dramatically higher." According to Olson, an all-digital video game world would be a tailwind for publishers like Activision Blizzard Inc., Electronic Arts Inc. and Take-Two Interactive Inc.
Follow RTT